idea-020 · human · US
For the quantitative determination of soluble fms-like tyrosine kinase-1; (sFlt-1) and placental growth factor (PlGF) in anticoagulated venous whole blood by trained; healthcare personnel in hospital labor-and-delivery and obstetric units, with the; sFlt-1/PlGF (soluble fms-like tyrosine kinase-1 to placental growth factor ratio) ratio used in conjunction with other clinical and laboratory information as an; aid in the risk assessment of pregnant women with singleton pregnancies between 23 weeks; 0 days and 34 weeks 6 days of gestation who are hospitalized for a hypertensive disorder of; pregnancy, for progression to preeclampsia with severe features within two weeks; not for; screening, not for the diagnosis of preeclampsia, and not for use outside the hospital.
Still being built — 5 of 8 wrap criteria met; nothing for you to decide yet. No department has been asked. 0 of 29 claims verified. Nobody has yet written down what it rests on.
A single-use microfluidic cartridge taking anticoagulated venous whole blood, separating plasma on-cartridge, and running two sandwich immunoassays (soluble fms-like tyrosine kinase-1 and placental growth factor) with fluorescent-label detection, read on a small benchtop reader that reports both concentrations and their ratio against the cutoff carried by the cleared predicate's labeling. The analytical design problem is precision at low PlGF concentrations, where the ratio is most sensitive to measurement error (claim 24unverified — reasoning, not a finding). Nothing here is a novel biomarker; the proposition is the same measurand pair, the same indication, run in a different place.
In the mechanism, as the candidate file states it — the plain-language paragraph in ## Wrap has not been written yet. Domain: none linked
No business case yet, so nothing here says who writes the cheque. /business-case idea-020 builds one.
What this idea rests on that is not yet known, in the order this idea's own decision queue puts it: worst if false first, cheapest to settle first inside that. The first row is open; open any other for what would settle it.
This idea is unassessed, so nobody has yet named the few things it rests on. Until then, the gaps below are the rubric factors that are unscored or carry an open question. /assess idea-020 replaces this list with the real one.
Why it scored what it did: intended_use: is present and copied from the predicate, so the factor is scoreable against it. Rests on claims 1 (DEN220027 (an FDA De Novo decision number) created 21 CFR (Title 21 of the Code of Federal Regulations) 862.1602 / QWH, Class II (FDA device class II)), 2 (predicate indication), 3 (Roche Elecsys reached the device type by…the rest of this reasoning
510(k) (premarket notification) in 2025, K-number unknown) and 7 (expected 510(k) evidence: analytical plus method-comparison/cutoff agreement, special controls unread). If 1-3 hold, a Class II 510(k) with two predicates is a good Factor 1 position. Held at 3, not 4: the device changes sample matrix (whole blood with on-cartridge separation) and site/operator (nursing staff on the L&D unit), either of which may pull in clinical-sample data in the hospitalized population beyond a bench comparison; claim 8unverified adds a CLIA (Clinical Laboratory Improvement Amendments) categorization step (moderate complexity at launch, waiver a separate study). The widened-indication route in device_class: is not scored.
What would settle it: FDA (US Food and Drug Administration)'s DEN220027 decision summary and the eCFR text of 21 CFR 862.1602 special controls (free, an hour), plus the Roche 510(k) record found by product-code QWH search in the FDA 510(k) database (free).
Why it scored what it did: Weak by construction, as the file itself says. Rests on claim 11unverified (inpatient labs paid inside the DRG, not separately, under IPPS and, believed, most state Medicaid methods), claim 9unverified (PLA 0524U exists but is test-specific; whether a new…the rest of this reasoning
manufacturer can report under it is unestablished) and claim 10unverified (0243U is a different test). A code existing does not make a pathway, and in this indication no per-test payment exists even if the code applied. The only revenue logic is claim 26unverified, an unsupported assumption that hospitals buy on their own operating economics. Not 0 because the hospital-economics route is a real (if unproven) purchasing path.
What would settle it: CMS (Centers for Medicare & Medicaid Services) IPPS rules on bundled inpatient lab services (free) and the AMA PLA code list entry for 0524U with its named test and lab (free); the hospital-economics case needs human-commissioned interviews with L&D and lab purchasers (paid).
Why it scored what it did: Placeholder for "unquantified", not an estimate. Component 1 (claim 12unverified: 3.60M US births 2023, 41.5% Medicaid) and component 2 (claim 13unverified: HDP 8.2%-15.9% of deliveries depending on source) are checkable and bound the HDP pool at very…the rest of this reasoning
roughly 0.3-0.6M pregnancies/year. Component 3 (claim 14unverified: the hospitalized 23+0 to 34+6 singleton subset) and component 4 (claim 15unverified: price per test) carry no figure, and addressable share (claim 16unverified: hospitals without an in-house cleared analyzer) and the obstetric-unit count (claim 17unverified) are assumptions. The in-indication subset is a fraction of the HDP pool and the payer model is a hospital budget line, so a small market is the likelier outcome; scored at the floor because the two components that set the size are unknown.
What would settle it: The CDC NVSR 2023 births report and the PMID (PubMed identifier) 35849460 abstract (free) settle components 1-2; the in-indication hospitalization rate needs a PRAECIS/HCUP-NIS inpatient antepartum-HDP query (free-to-low cost), and price plus hospital count…the rest of this gap analysis
need ARUP/Mayo send-out pricing and AHA survey data attached by a human (paid).
Why it scored what it did: Rests on claims 21 (US10302657B2, serial/dynamic ratio, assignee believed Roche), 22 (US 10,357,469, nothing known) and 23 (BIDMC/Karumanchi foundational families, believed early-2000s and possibly expired, no US number). Three names are…the rest of this reasoning
better than none, and the core measurand pair may be off-patent, but the claims of none were read and the point-of-care cartridge, on-cartridge plasma separation and ratio-reporting field is explicitly unsearched. Scored as unexamined with named leads, not as clear.
What would settle it: USPTO (United States Patent and Trademark Office) Patent Center status and claims for the two named patents plus a family search for the BIDMC US members (free, a few hours); a CPC sweep of Roche/Thermo Fisher/QuidelOrtho filings on sFlt-1/PlGF and whole-blood cartridges would…the rest of this gap analysis
complete the landscape.
Why it scored what it did: No claim addresses moat directly; inferred from claims 24-25 and 27. The measurand, cutoff and indication are all public and held by the predicate, so the only assets are cartridge engineering (low-end PlGF precision, whole-blood…the rest of this reasoning
separation) and first-mover clearance in a niche. Roche and Thermo Fisher own the calibration lineage and could follow; QuidelOrtho already sells a POC PlGF assay abroad (claim 4unverified). IP (intellectual property) moat is unknowable while FTO (freedom to operate)/IP is unexamined.
What would settle it: Falls out of the FTO/IP patent sweep (free); an FDA 510(k) database check for other QWH filers since 2023 (free) gauges how fast followers arrive.
Why it scored what it did: Clinical risk is low if claims 5-6 hold: PRAECIS (US, 1014 hospitalized women, ratio ≥40 sens/spec 81%/81%, NPV 90%) and PROGNOSIS validate the biomarker, and claims 1-3 say FDA has cleared it twice. The risk is analytical, not biological:…the rest of this reasoning
claim 24unverified (reasoning) names low-PlGF imprecision, hematocrit/hemolysis effects, lot drift and non-commutability with predicate calibration, and claim 25unverified says no prototype or data exist. Held at 3 because matching central-lab precision near the cutoff in a whole-blood cartridge is an unproven engineering bet.
What would settle it: The PRAECIS and PROGNOSIS papers via PubMed/DOI (free) settle the clinical half; the analytical half needs a bench feasibility study on banked samples against a KRYPTOR or Elecsys (paid, months).
Why it scored what it did: Inferred from claims 7-8, 24-25 and 11/26. A new reader plus microfluidic dual-immunoassay cartridge built from zero (claim 25unverified), then analytical validation, method comparison on hospitalized-HDP samples, 510(k) and CLIA categorization, and…the rest of this reasoning
first sales as unreimbursed hospital capital/consumable purchases. That points to a multi-year, multi-million-dollar IVD (in vitro diagnostic) program with a slow first dollar. Not 1 because the regulatory evidence burden, if claim 7unverified holds, stops short of an outcome study.
What would settle it: A human estimate from IVD contract developers for a two-analyte fluorescent cartridge-and-reader program (a few quotes, free to request), with the special-controls read under Regulatory setting the clinical-study size.
Why it scored what it did: Rests on claims 3, 4, 18 and 27. Two large incumbents (Thermo Fisher KRYPTOR, Roche Elecsys) own the device type but only on central-lab analyzers; reference labs (ARUP, Mayo) serve the send-out case; no US POC sFlt-1/PlGF test was found,…the rest of this reasoning
though that is a web-search absence. QuidelOrtho's ex-US POC PlGF product is the obvious latent entrant. Moderate: an open format niche beside well-resourced incumbents who could close it.
What would settle it: An FDA 510(k)/De Novo database search on product code QWH plus ClinicalTrials.gov for POC sFlt-1/PlGF studies (free, an hour).
Why it scored what it did: Left unscored: no claim in this file addresses portfolio fit and no portfolio thesis exists in this repo to score against.
What would settle it: A Tier 3 human portfolio statement at Stage 6; not closable by a Verifier pass.
Seven chairs, each answering from its own field. The verdict, and the first condition it set.
Not convened. No department has stated a position on this idea yet — a normal state, not a defect. /round-table idea-020 asks all seven.
Only verified counts toward a score. A low count is usually a statement about the tooling — an absent data file, an unset key — rather than about the idea.
No claim on this idea has been refuted.
<one sentence, selected from the Scores table's "What would settle it" column>
Nothing is waiting on a decision. The next move above is work, not a choice.
Only verified counts toward a score. A low count is usually a statement about the tooling (an absent data file, an unset key) rather than about the idea.
To finish it:
domains: — run /research**Cheapest next test:** is still the unfilled _template.md placeholder — name the test, or the criterion checks nothingNo human review is recorded. Shortlisting, legal and clinical sign-off and capital allocation are Tier 3: no agent in this repo makes or simulates one.
Runs only after a human shortlists the idea.
No loop record: nobody has written down what this idea rests on or convened a department on it. That is a normal state, not a defect. /front-end-loop idea-020 opens one.
Nobody has yet written down what this idea rests on and what it would cost to be wrong. Unassessed is a state, not a low score. /assess idea-020 adds it.
Click any step to see what it holds for this idea. donecurrentloopinghuman only
## Wrap section, as writtenThe packet a human reads. See docs/wrap-spec.md. This section says nothing about whether the idea is good — it says the file is finished enough to be read, and names what to do next. Filling it in advances no candidate and approves nothing.
The one-paragraph version. <not yet written — later-stage artifact>
What would have to be true.
Cheapest next test: <one sentence, selected from the Scores table's "What would settle it" column>
Where the evidence actually stands. <run python3 engine/scripts/wrap_status.py --candidate idea-020>
| Factor | Score | Why | What would settle it |
|---|---|---|---|
| Regulatory pathway | 3 | intended_use: is present and copied from the predicate, so the factor is scoreable against it. Rests on claims 1 (DEN220027 created 21 CFR 862.1602 / QWH, Class II), 2 (predicate indication), 3 (Roche Elecsys reached the device type by…the rest of this reasoning510(k) in 2025, K-number unknown) and 7 (expected 510(k) evidence: analytical plus method-comparison/cutoff agreement, special controls unread). If 1-3 hold, a Class II 510(k) with two predicates is a good Factor 1 position. Held at 3, not 4: the device changes sample matrix (whole blood with on-cartridge separation) and site/operator (nursing staff on the L&D unit), either of which may pull in clinical-sample data in the hospitalized population beyond a bench comparison; claim 8unverified adds a CLIA categorization step (moderate complexity at launch, waiver a separate study). The widened-indication route indevice_class: is not scored. | FDA's DEN220027 decision summary and the eCFR text of 21 CFR 862.1602 special controls (free, an hour), plus the Roche 510(k) record found by product-code QWH search in the FDA 510(k) database (free). |
| Reimbursement pathway | 1 | Weak by construction, as the file itself says. Rests on claim 11unverified (inpatient labs paid inside the DRG, not separately, under IPPS and, believed, most state Medicaid methods), claim 9unverified (PLA 0524U exists but is test-specific; whether a new…the rest of this reasoningmanufacturer can report under it is unestablished) and claim 10unverified (0243U is a different test). A code existing does not make a pathway, and in this indication no per-test payment exists even if the code applied. The only revenue logic is claim 26unverified, an unsupported assumption that hospitals buy on their own operating economics. Not 0 because the hospital-economics route is a real (if unproven) purchasing path. | CMS IPPS rules on bundled inpatient lab services (free) and the AMA PLA code list entry for 0524U with its named test and lab (free); the hospital-economics case needs human-commissioned interviews with L&D and lab purchasers (paid). |
| TAM | 2 | Placeholder for "unquantified", not an estimate. Component 1 (claim 12unverified: 3.60M US births 2023, 41.5% Medicaid) and component 2 (claim 13unverified: HDP 8.2%-15.9% of deliveries depending on source) are checkable and bound the HDP pool at very…the rest of this reasoningroughly 0.3-0.6M pregnancies/year. Component 3 (claim 14unverified: the hospitalized 23+0 to 34+6 singleton subset) and component 4 (claim 15unverified: price per test) carry no figure, and addressable share (claim 16unverified: hospitals without an in-house cleared analyzer) and the obstetric-unit count (claim 17unverified) are assumptions. The in-indication subset is a fraction of the HDP pool and the payer model is a hospital budget line, so a small market is the likelier outcome; scored at the floor because the two components that set the size are unknown. | The CDC NVSR 2023 births report and the PMID 35849460 abstract (free) settle components 1-2; the in-indication hospitalization rate needs a PRAECIS/HCUP-NIS inpatient antepartum-HDP query (free-to-low cost), and price plus hospital count…the rest of this gap analysisneed ARUP/Mayo send-out pricing and AHA survey data attached by a human (paid). |
| FTO / IP | 2 | Rests on claims 21 (US10302657B2, serial/dynamic ratio, assignee believed Roche), 22 (US 10,357,469, nothing known) and 23 (BIDMC/Karumanchi foundational families, believed early-2000s and possibly expired, no US number). Three names are…the rest of this reasoningbetter than none, and the core measurand pair may be off-patent, but the claims of none were read and the point-of-care cartridge, on-cartridge plasma separation and ratio-reporting field is explicitly unsearched. Scored as unexamined with named leads, not as clear. | USPTO Patent Center status and claims for the two named patents plus a family search for the BIDMC US members (free, a few hours); a CPC sweep of Roche/Thermo Fisher/QuidelOrtho filings on sFlt-1/PlGF and whole-blood cartridges would…the rest of this gap analysiscomplete the landscape. |
| Moat / defensibility | 2 | No claim addresses moat directly; inferred from claims 24-25 and 27. The measurand, cutoff and indication are all public and held by the predicate, so the only assets are cartridge engineering (low-end PlGF precision, whole-blood…the rest of this reasoningseparation) and first-mover clearance in a niche. Roche and Thermo Fisher own the calibration lineage and could follow; QuidelOrtho already sells a POC PlGF assay abroad (claim 4unverified). IP moat is unknowable while FTO/IP is unexamined. | Falls out of the FTO/IP patent sweep (free); an FDA 510(k) database check for other QWH filers since 2023 (free) gauges how fast followers arrive. |
| Mechanism & clinical risk | 3 | Clinical risk is low if claims 5-6 hold: PRAECIS (US, 1014 hospitalized women, ratio ≥40 sens/spec 81%/81%, NPV 90%) and PROGNOSIS validate the biomarker, and claims 1-3 say FDA has cleared it twice. The risk is analytical, not biological:…the rest of this reasoningclaim 24unverified (reasoning) names low-PlGF imprecision, hematocrit/hemolysis effects, lot drift and non-commutability with predicate calibration, and claim 25unverified says no prototype or data exist. Held at 3 because matching central-lab precision near the cutoff in a whole-blood cartridge is an unproven engineering bet. | The PRAECIS and PROGNOSIS papers via PubMed/DOI (free) settle the clinical half; the analytical half needs a bench feasibility study on banked samples against a KRYPTOR or Elecsys (paid, months). |
| Capital intensity & time-to-revenue | 2 | Inferred from claims 7-8, 24-25 and 11/26. A new reader plus microfluidic dual-immunoassay cartridge built from zero (claim 25unverified), then analytical validation, method comparison on hospitalized-HDP samples, 510(k) and CLIA categorization, and…the rest of this reasoningfirst sales as unreimbursed hospital capital/consumable purchases. That points to a multi-year, multi-million-dollar IVD program with a slow first dollar. Not 1 because the regulatory evidence burden, if claim 7unverified holds, stops short of an outcome study. | A human estimate from IVD contract developers for a two-analyte fluorescent cartridge-and-reader program (a few quotes, free to request), with the special-controls read under Regulatory setting the clinical-study size. |
| Competitive intensity | 3 | Rests on claims 3, 4, 18 and 27. Two large incumbents (Thermo Fisher KRYPTOR, Roche Elecsys) own the device type but only on central-lab analyzers; reference labs (ARUP, Mayo) serve the send-out case; no US POC sFlt-1/PlGF test was found,…the rest of this reasoningthough that is a web-search absence. QuidelOrtho's ex-US POC PlGF product is the obvious latent entrant. Moderate: an open format niche beside well-resourced incumbents who could close it. | An FDA 510(k)/De Novo database search on product code QWH plus ClinicalTrials.gov for POC sFlt-1/PlGF studies (free, an hour). |
| Strategic fit & portfolio balance | — | Left unscored: no claim in this file addresses portfolio fit and no portfolio thesis exists in this repo to score against. | A Tier 3 human portfolio statement at Stage 6; not closable by a Verifier pass. |
To finish this packet:
domains: — run /research**Cheapest next test:** is still the unfilled _template.md placeholder — name the test, or the criterion checks nothingSource file: knowledge-base/candidates/idea-020.md
Nothing on this page is a recommendation. Shortlist review, legal and clinical sign-off and capital allocation are human-only decisions, and no agent in this repo may make or simulate one. This is a compilation of what the candidate file says.
_shared/plain-language.md